TP53 and neoplasm: TP53 is mutated in approximately 30% of breast cancers [1], but the clinical relevance of mutant status in a tumor is muddled by different studies that show TP53 mutation can be detrimental, neutral, or beneficial to outcome (for examples/review, see [3–6]).